2116 related articles for article (PubMed ID: 32385712)
1. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy D; Gilligan MM; Huang S; Gartung A; Cortés-Puch I; Sime PJ; Phipps RP; Serhan CN; Hammock BD
Cancer Metastasis Rev; 2020 Jun; 39(2):337-340. PubMed ID: 32385712
[TBL] [Abstract][Full Text] [Related]
2. Eicosanoids: The Overlooked Storm in Coronavirus Disease 2019 (COVID-19)?
Hammock BD; Wang W; Gilligan MM; Panigrahy D
Am J Pathol; 2020 Sep; 190(9):1782-1788. PubMed ID: 32650004
[TBL] [Abstract][Full Text] [Related]
3. Effects of sEH inhibition on the eicosanoid and cytokine storms in SARS-CoV-2-infected mice.
Edin ML; Gruzdev A; Graves JP; Lih FB; Morisseau C; Ward JM; Hammock BD; Bosio CM; Zeldin DC
FASEB J; 2024 May; 38(10):e23692. PubMed ID: 38786655
[TBL] [Abstract][Full Text] [Related]
4. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.
Zhang X; Zhang Y; Qiao W; Zhang J; Qi Z
Int Immunopharmacol; 2020 Sep; 86():106749. PubMed ID: 32645632
[TBL] [Abstract][Full Text] [Related]
5. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions.
Jafarzadeh A; Chauhan P; Saha B; Jafarzadeh S; Nemati M
Life Sci; 2020 Sep; 257():118102. PubMed ID: 32687918
[TBL] [Abstract][Full Text] [Related]
6. Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators.
Yasmeen N; Selvaraj H; Lakhawat SS; Datta M; Sharma PK; Jain A; Khanna R; Srinivasan J; Kumar V
Biochem Pharmacol; 2023 Mar; 209():115437. PubMed ID: 36731803
[TBL] [Abstract][Full Text] [Related]
7. Specialized pro-resolving mediator network: an update on production and actions.
Chiang N; Serhan CN
Essays Biochem; 2020 Sep; 64(3):443-462. PubMed ID: 32885825
[TBL] [Abstract][Full Text] [Related]
8. COVID-19 and cancer: start the resolution!
Barksdale C; Kipper FC; Tripathy S; Subbian S; Serhan CN; Panigrahy D
Cancer Metastasis Rev; 2022 Mar; 41(1):1-15. PubMed ID: 35190921
[TBL] [Abstract][Full Text] [Related]
9.
Siddiqui R; Khan NA
ACS Chem Neurosci; 2020 Aug; 11(16):2391-2392. PubMed ID: 32786329
[TBL] [Abstract][Full Text] [Related]
10. Specialized pro-resolving lipid mediators regulate inflammatory macrophages: A paradigm shift from antibiotics to immunotherapy for mitigating COVID-19 pandemic.
Kumar V; Yasmeen N; Chaudhary AA; Alawam AS; Al-Zharani M; Suliman Basher N; Harikrishnan S; Goud MD; Pandey A; Lakhawat SS; Sharma PK
Front Mol Biosci; 2023; 10():1104577. PubMed ID: 36825200
[TBL] [Abstract][Full Text] [Related]
11. The COVID-19 Cytokine Storm; What We Know So Far.
Ragab D; Salah Eldin H; Taeimah M; Khattab R; Salem R
Front Immunol; 2020; 11():1446. PubMed ID: 32612617
[TBL] [Abstract][Full Text] [Related]
12. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
13. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19.
Dalamaga M; Karampela I; Mantzoros CS
Metabolism; 2020 Aug; 109():154282. PubMed ID: 32497535
[TBL] [Abstract][Full Text] [Related]
14. Tackling the cytokine storm in COVID-19, challenges and hopes.
Abdin SM; Elgendy SM; Alyammahi SK; Alhamad DW; Omar HA
Life Sci; 2020 Sep; 257():118054. PubMed ID: 32663575
[TBL] [Abstract][Full Text] [Related]
15. The case for chronotherapy in Covid-19-induced acute respiratory distress syndrome.
Tamimi F; Abusamak M; Akkanti B; Chen Z; Yoo SH; Karmouty-Quintana H
Br J Pharmacol; 2020 Nov; 177(21):4845-4850. PubMed ID: 32442317
[TBL] [Abstract][Full Text] [Related]
16. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response.
Arnaldez FI; O'Day SJ; Drake CG; Fox BA; Fu B; Urba WJ; Montesarchio V; Weber JS; Wei H; Wigginton JM; Ascierto PA
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385146
[TBL] [Abstract][Full Text] [Related]
17. Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19.
Conti P; Caraffa A; Tetè G; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1629-1632. PubMed ID: 32945158
[TBL] [Abstract][Full Text] [Related]
18. IL-15 immunotherapy is a viable strategy for COVID-19.
Kandikattu HK; Venkateshaiah SU; Kumar S; Mishra A
Cytokine Growth Factor Rev; 2020 Aug; 54():24-31. PubMed ID: 32536564
[TBL] [Abstract][Full Text] [Related]
19. The role of Interleukin 6 inhibitors in therapy of severe COVID-19.
Nasonov E; Samsonov M
Biomed Pharmacother; 2020 Nov; 131():110698. PubMed ID: 32920514
[TBL] [Abstract][Full Text] [Related]
20. Rationale for targeting complement in COVID-19.
Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
